PUBLISHER: The Business Research Company | PRODUCT CODE: 1945471
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945471
A left atrial appendage closure device is a medical implant employed in the treatment of specific heart conditions, particularly in patients with atrial fibrillation (AF). These devices are surgically implanted in a minimally invasive procedure to mitigate the risk of stroke in AF patients. The primary mechanism involves sealing off or occluding the left atrial appendage (LAA), thereby preventing the entry and clotting of blood.
The two main categories of products within left atrial appendage closure devices are epicardial left atrial appendage (LAA) devices and endocardial left atrial appendage (LAA) devices. Epicardial left atrial appendage (LAA) devices encompass medical devices and techniques utilized for the closure or exclusion of the left atrial appendage from the exterior of the heart. This category includes both percutaneous and surgical procedures, with various end-users such as hospitals, ambulatory surgical centers, and other medical facilities.
Tariffs are impacting the left atrial appendage closure device market by increasing costs of imported implant-grade metals, polymers, delivery catheters, imaging components, and precision manufacturing tools. Cardiac care centers in North America and Europe are most affected due to dependence on imported structural heart devices, while Asia-Pacific faces pricing pressure on device exports. These tariffs are increasing procedure costs and procurement complexity. However, they are also driving domestic manufacturing initiatives, regional supply chain localization, and innovation in cost-efficient cardiac implant technologies.
The left atrial appendage closure device market research report is one of a series of new reports from The Business Research Company that provides left atrial appendage closure device market statistics, including left atrial appendage closure device industry global market size, regional shares, competitors with a left atrial appendage closure device market share, detailed left atrial appendage closure device market segments, market trends and opportunities, and any further data you may need to thrive in the left atrial appendage closure device industry. This left atrial appendage closure device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The left atrial appendage closure device market size has grown rapidly in recent years. It will grow from $1.99 billion in 2025 to $2.33 billion in 2026 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to increasing prevalence of atrial fibrillation, rising stroke incidence among aging populations, expansion of interventional cardiology procedures, growing availability of minimally invasive cardiac treatments, improved clinical outcomes data.
The left atrial appendage closure device market size is expected to see rapid growth in the next few years. It will grow to $4.37 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to increasing adoption of non-pharmacological stroke prevention, expansion of cardiac catheterization labs, growing demand for personalized cardiac implants, rising investments in structural heart disease treatments, technological advancements in implant materials and delivery systems. Major trends in the forecast period include increasing adoption of minimally invasive cardiac implants, rising demand for stroke prevention devices, growing use of percutaneous laa closure procedures, expansion of advanced occlusion device designs, enhanced focus on patient-specific cardiac solutions.
The increasing prevalence of atrial fibrillation is anticipated to drive the growth of the left atrial appendage (LAA) closure device market in the coming years. Atrial fibrillation is a cardiac condition marked by an irregular and frequently rapid heart rhythm. It occurs when the upper chambers of the heart, known as the atria, fail to contract in a synchronized and orderly manner. Left atrial appendage (LAA) closure devices are mainly used in the management of atrial fibrillation to lower the risk of stroke in affected patients by preventing blood clots from forming in or escaping from the appendage. For example, in May 2024, according to the Centers for Disease Control and Prevention, a US-based public health agency, the number of adults living with atrial fibrillation in the United States reached an estimated 12.1 million in 2023, rising from around 5.2 million in 2022. Therefore, the growing prevalence of atrial fibrillation is fueling the expansion of the left atrial appendage (LAA) closure device market.
Major companies operating in the left atrial appendage closure device market are emphasizing technological advancements, including expanded-size, radiopaque-marked closure systems with advanced polymer coatings, to improve procedural precision, visualization, and patient safety while addressing a wider range of left atrial appendage anatomies. Expanded-size, radiopaque-marked closure systems incorporate multiple device size options, radiopaque markers, and biocompatible polymer coatings to support accurate fluoroscopic placement, lower stroke risk associated with atrial fibrillation, and reduce complications linked to long-term anticoagulation therapy. For example, in April 2024, Boston Scientific Japan Co., Ltd., a Tokyo-based cardiovascular medical device company, introduced the WATCHMAN FLX Pro Left Atrial Appendage Closure System across Japan. This next-generation system includes a new 40 mm device designed for larger left atrial appendages, features three radiopaque markers to enhance implantation visibility, and utilizes the HEMOCOAT polymer coating with an established clinical history, improving procedural effectiveness, safety, and therapeutic options for patients with non-valvular atrial fibrillation.
In November 2023, Johnson & Johnson MedTech, a US-based medical technology company, acquired Laminar, Inc. for an upfront payment of $400 million, with additional milestone-based payments expected in 2024 and subsequent years. Through this acquisition, Johnson & Johnson MedTech seeks to reinforce its presence in high-growth cardiac device segments by incorporating Laminar's innovative left atrial appendage elimination technology, which is designed to reduce stroke risk in patients with non-valvular atrial fibrillation. Laminar, Inc. is a US-based privately held medical device company focused on developing left atrial appendage elimination solutions.
Major companies operating in the left atrial appendage closure device market are Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, AtriCure Inc, Lifetech Scientific Corporation, Occlutech GmbH, Cardia Inc, SentreHEART Inc, Coherex Medical Inc, Lepu Medical Technology Co Ltd, MicroPort Scientific Corporation, NMT Medical Inc, Transcatheter Technologies GmbH, Shanghai Shape Memory Alloy Co Ltd, Braile Biomedica, Innovative Cardiovascular Solutions LLC, Eclipse Medical, PushMed (PushMed Medical), Cardiawave, Catheter Precision Inc.
North America was the largest region in the left atrial appendage closure devices market in 2025. The regions covered in the left atrial appendage closure device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the left atrial appendage closure device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The left atrial appendage closure device market consists of sales of transcatheter devices, suture delivery devices, sealing material, delivery catheters, and imaging markers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Left Atrial Appendage Closure Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses left atrial appendage closure device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for left atrial appendage closure device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The left atrial appendage closure device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.